TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cutaneous melanoma with Breslow depth \> 1 mm or melanoma Breslow depth of 0.76 - 1.00 mm in setting of ulceration, extensive regression~* Mitotic rate \>= 1/mm\^2~* Presence of angiolymphatic invasion~* Deep positive margin~* No known allergies to contrast material~Exclusion Criteria:~* Pregnant or nursing~* Patients with known cardiac shunt~* Patients with class II heart failure or worse, per New York Heart Association (NYHA) classification~* Patients who have experienced an acute coronary syndrome or angina in the past 6 months~* Patients who have undergone coronary artery bypass grafting (CABG) or coronary stenting in the past 3 years~* Patients with evidence of moderate or severe cardiac valvular disease on echocardiogram~* Patients with evidence of moderate or severe pulmonary hypertension on echocardiogram~* Patients with stage II chronic obstructive pulmonary disease (COPD) or worse, per Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification~* Patients with hypersensitivity to sonazoid or one of its components~* Patients with hypersensitivity to egg or egg products, because sonazoid contains a chicken egg-derived surfactant (hydrogenated egg phosphatidylserine sodium)~* Patients who cannot consent for themselves

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (sonazoid, ultrasound imaging, SLNB) (Type: EXPERIMENTAL): Patients receive sonazoid ID and undergo ultrasound imaging. Patients also undergo standard of care SLNB.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Piecemeal Versus En Bloc Resection of Large Rectal Adenomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with large non pedunculated colorectal adenomas designated for endoscopic resection up to 15 cm ab ano, length 2 cm to 5 cm, maximum hemicircumferential~* age \> 18 years~* signed Informed Consent~Exclusion Criteria:~* adenomas smaller or larger than described above~* more than one large rectal adenoma~* adenomas with known or suspected carcinoma, proven by previous biopsies~* adenomas with known or suspected carcinoma that do not seem to be resectable by endoscopy, e.g. ulcers, suspected infiltration of submucosa after endoscopic or ultrasound diagnostics~* patients with chronic inflammatory bowel diseases~* severe general disease, including metastasising carcinomas~* coagulation abnormalities or anticoagulant drug use which make resection therapy impossible~* bad general state of health (American Society of Anesthesiologists Classification (ASA) IV or more)~* pregnancy and lactation~* recurrence or leftover dysplasia after extended endoscopic or surgical therapy (transanal endoscopic microsurgery (TEM))

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- en-bloc resection (Type: EXPERIMENTAL): En- bloc resection is done after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily. Since the aim of this method is the total resection basally and laterally, only one session is intended.
- piecemeal resection (Type: ACTIVE_COMPARATOR): Piecemeal resection will be done by snare following marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps. High resolution endoscopes are mandatory.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done. This second session can be done by sigmoidoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TRAUMEEL for Pain After Total Knee/Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of either sex undergoing unilateral THAP or TKAP.~* Age over 18 years.~* Signature upon informed consent form~Exclusion Criteria:~* Participation in another clinical trial within 4 weeks prior to enrollment.~* Refused to give verbal consent to the telephone interviews~* Impossibility to be reached during the 14-17 days post operative~* Inability to comply with the study protocol for any other reason~* Previous major surgical procedure on ipsilateral leg.~* Current use of analgesics for any other reason.~* A history of chronic pain syndrome.~* Abused legal or illicit drug use.~* Hypersensitivity to botanicals of the Compositae family~* Known sensitivity to paracetamol, codeine or tramadol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): TraumeelS
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with stage T3 or T4 squamous cell carcinoma of the oropharynx previously untreated.~* Performance status 0 or 1~* Tumor histology proving squamous cell carcinoma~Exclusion Criteria:~* Visceral metastases at initial assessment~* Contraindication to surgery and / or chemotherapy such as:~* A history of other cancer (except basal cell carcinoma skin or cervical cancer in situ)~* 2nd associated cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ability to swallow, speak and quality of life (Type: None): This will just be an evaluation, before any treatment, his ability to swallow, speak and quality of life then, as in normal practice, after 3, 6 and 12 months after treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Short- Versus Long-duration Tourniquet Use During Total Knee Replacement (TKR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary, unilateral knee replacement;~* capacity to understand the protocol;~Exclusion Criteria:~* inability to read English;~* current warfarin therapy (or similar);~* significant PVD, peripheral arterial disease or diabetes rendering tourniquet use undesirable;~* evidence of chronic or recent DVT in index limb;~* thigh circumference \> 100 cm (approximately);~* Jehovah's Witness (ie refusal to receive donor blood)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Short duration tourniquet (Type: EXPERIMENTAL): Patients allocated to this group will have the pneumatic tourniquet applied to the index limb for approximately 20-30 minutes during cement fixation of the prosthesis.
- Long duration tourniquet (Type: ACTIVE_COMPARATOR): Patients randomised to this arm will have the tourniquet applied from commencement of surgery and removed just prior to skin closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with out of hospital cardiac arrest and successful cardiopulmonary resuscitation, which will be treated at Department of Internal Medicine I, University Hospital Aachen~Exclusion Criteria:~* Patients younger than 18 years~* Xenon allergy~* Pregnancy~* High expired oxygen requirement (\>70%) in order to maintain adequate arterial oxygen saturation (SpO2\>94%) at the beginning of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xenon-Arm (Type: EXPERIMENTAL): Patients in Xenon-Arm will be inhalated with xenon within 2 hours additionally to therapeutical hypothermia after successful cardiopulmonary resuscitation.
- MTH (Type: ACTIVE_COMPARATOR): Patients after successful cardiopulmonary resuscitation will be treated only with therapeutical hypothermia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imaging of Peri-operative (periOP) Lung Injury

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II: forced expiratory volume 1 (FEV1)/forced vital capacity (FVC) \<0.70 and FEV1 50-79% normal) undergoing Whipple procedures or other major surgeries~* Patients with normal lung function undergoing Whipple procedures or other major abdominal surgeries~Exclusion Criteria:~* Age \< 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal preoperative lung function (Type: OTHER): Patients with normal lung function undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
- Preoperative COPD (Type: OTHER): Patients with moderate COPD undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of FDG PET and Bone Scintigraphy/Labelled Leukocyte/Gallium Scintigraphy in Diabetic Foot Osteomyelitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetic patient with suspected diabetic foot osteomyelitis referred for nuclear medicine examination (bone scan and Gallium or labelled leukocytes).~* Being treated or followed by a physician at CHUM~Exclusion Criteria:~* Pregnant woman~* Breastfeeding patient~* Claustrophobia/patient unable to complete imaging procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Main arm (Type: EXPERIMENTAL): PET-CT imaging of the ankles and feet following injection of 18F-FDG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Any age at the day of screening visit.~* No known or suspected clinically significant disease from AdV, BKV, CMV, EBV, HHV-6, and/or JCV~* Within 25 days of receiving a first allogeneic HCT and have demonstrated clinical engraftment at time of dosing~* Meet one or more of the following criteria at the time of randomization:~  * Related (sibling) donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B or -DR~ * Haploidentical donor~ * Matched or Mismatched unrelated donor~ * Use of umbilical cord blood as stem cell source~ * Ex vivo graft manipulation resulting in T cell depletion~ * Received anti-thymocyte globulin or alemtuzumab (Campath-1H)~Key Exclusion Criteria:~* History of AdV, BKV, CMV, EBV, HHV-6, and/or JCV end-organ disease within 6 months prior to randomization~* Evidence of active Grade \>2 acute GVHD~* Presence of non-minor uncontrolled or progressive bacterial, viral or fungal infections~* Known history or current (suspected) diagnosis of Grade ≥3 CRS requiring treatment associated with the administration of peptides, proteins, and/or antibodies~* Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose \>1.0 mg/kg/day) within 24 hours prior to dosing~* Relapse of primary malignancy other than minimal residual disease~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Posoleucel (ALVR105) (Type: EXPERIMENTAL): Administered as 2-4 milliliter infusion, visually identical to placebo
- Placebo (Type: PLACEBO_COMPARATOR): Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Environmental and Genetic Determinants of NPC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Eligibility criteria for cases:~* Incident diagnosis of NPC between 2010-2015~* Age greater than or equal to 21 years at NPC diagnosis~* Histologically confirmed~* Resident of northern Taiwan greater than or equal to 6 months~Eligibility criteria for controls:~* Resident of northern Taiwan greater than or equal to 6 months~* Matched to case based on age at diagnosis, gender, and ethnicity~EXCLUSION CRITERIA:~Exclusion criteria for controls:~- Clinic attendance due to conditions associated with EBV or smoking

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Cases with NPC (Type: None): Cases with NPC
- Hospital based controls (Type: None): Hospital based controls

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eligibility for living donor ABO-incompatible kidney transplantation according to center standard~* Age \>18 years~* Signed written informed consent~* Negative cytotoxic and flow-cytometric crossmatch~Exclusion Criteria:~* Age\<18 years~* No signed written informed consent~* Blood group AB (no isoagglutinins)~* Pregnant and breastfeeding women~* HLA-sensitized patients (i.e. patients with preformed antibodies against donor HLA antigens)~* Positive cytotoxic and flow-cytometric crossmatch~* Severe blood coagulation disorder precluding the use of membrane filtration or immunoadsorption~* Initial serum fibrinogen \<200mg/dL~* IgA deficiency~* Any severe disease (e.g. severe infection) precluding ABOi-KTX~* Heparin intolerance~* Polysulfone intolerance~* Participation in any other intervention trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Combined apheresis (Type: EXPERIMENTAL): Patients will be treated by semiselective immunoadsorption combined with membrane filtration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Usability Testing of Affordable Haptic Robots for Stroke Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stroke survivors at least 18 years of age with hemiplegia.~* The subject's stroke must have occurred at least 3 months prior to enrollment in the study.~* Low and Moderate functioning stroke survivors as measured by Fugl- Meyer~* Not depressed~* No more than Mild Cognitive Deficit~* Participants must be able to sit upright for 4 hours at a time in Part A of the study; and 2 hours at a time, 3 days a week, for Part B of the study.~* The subject's stroke must have occurred at least 3 months prior to enrollment in the study.~Exclusion Criteria:~* Greater than mild cognitive deficits~* Greater than mild depression. A member of the research team will administer Beck's Depression Inventory (BDI) to each study participant over the phone. If the participant is found to have greater than mild depression, as measured by the BDI, they will not qualify for the study.~* Receiving rehabilitation on the upper limb.~* Received Botox injections within the past 3 months.~* Suffering from contractures (chronic loss of joint motion) or debilitating spasticity in the upper extremity.~* Experiencing greater than mild pain, and/or the PI determines that the participant should no longer continue working with the novel therapy devices, the study will be stopped.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stroke survivors with low and moderate motor deficits (Type: OTHER): Subjects with low and moderate motor deficits will 1) complete exercises with 2 commercial (joystick and wheel) and the Theradrive haptic robot after pre assessment 2) then experience 12 therapy sessions on the Theradrive haptic robot with Adaptive Feedback. 3) Assessments pre and post therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Enable I Long-term Follow-up Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who were enrolled and implanted for the ATS 3f Enable™ Aortic Bioprosthesis Model 6000, number S2005~* Patient willing to sign the new Data Release form (DRF) or Patient Informed Consent (PIC) for the post-market study (what is applicable for the study due to local requirements and regulations)~Exclusion Criteria:~* ATS 3f Enable™ Aortic Bioprosthesis Model 6000 was explanted~* Patient died~* Patient lost to follow-up~* Patient withdrew consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Site Study of the Zyga GlyDer Facet Restoration Device In Subjects With LUmbar FacET Pain Syndrome - DUET

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Confirmed bilateral facet joint disease demonstrated by a successful facet rhizotomy (neural ablation) within 18 months prior to enrollment~2. Facet pain is limited to one to two levels from L2 to the sacrum and pain is bilateral~3. Two diagnostic injections (MBBs) both resulting in 80% relief to confirm back pain is facetogenic~4. VAS back pain of ≥ 60 mm on a 100 mm scale, and VAS back pain is greater than or equal to the highest VAS leg pain score~5. ODI ≥ 20 points~6. At least six (6) months of non-operative conservative management (Analgesic therapy for a minimum of 2 weeks and a minimum of 4 weeks of NSAID therapy; Supervised exercise and/or physical therapy program-minimum of 12 sessions)~7. At least 22 years of age and skeletally mature~Key Exclusion Criteria:~1. Pain is from a spinal structure other than facet joints (i.e., disc, hip and SI joint pain are excluded)~2. Osteoporosis or severe osteopenia~3. Lumbar fusion~4. Symptomatic spinal stenosis requiring surgical intervention~5. Prior total disc replacement, fusion, decompressive laminectomy, facetectomy, or placement of a posterior spinous process device~6. Disc herniation requiring surgical intervention~7. The subject has a Body Mass Index (BMI) of greater than 35~8. Planned elective surgery within 12 months

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glyder (Type: EXPERIMENTAL): Glyder Facet Restoration Device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues